within Pharmacolibrary.Drugs.ATC.B;

model B01AD04
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 7.666666666666667e-07,
    adminDuration  = 600,
    adminMass      = 2500000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00011,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 7.199999999999999e-05,
    k12             = 0.02,
    k21             = 0.02
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AD04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Urokinase is a thrombolytic agent, a serine protease enzyme used to dissolve blood clots. It activates plasminogen to plasmin, which in turn degrades fibrin and dissolves clots. Urokinase is indicated for the treatment of pulmonary embolism, myocardial infarction, and occluded intravenous or dialysis catheters. It is approved for clinical use in various countries for selected indications but has been largely replaced by other agents in some regions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult males receiving intravenous administration.</p><h4>References</h4><ol><li><p>Piechowski-Jozwiak, B, et al., &amp; Bogousslavsky, J (2022). Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase. <i>European journal of drug metabolism and pharmacokinetics</i> 47(2) 165–176. DOI:<a href=\"https://doi.org/10.1007/s13318-021-00743-8\">10.1007/s13318-021-00743-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34893967/\">https://pubmed.ncbi.nlm.nih.gov/34893967</a></p></li><li><p>Mateusiak, Ł, et al., &amp; Hernot, S (2024). Generation and Characterization of Novel Pan-Cancer Anti-uPAR Fluorescent Nanobodies as Tools for Image-Guided Surgery. <i>Advanced science (Weinheim, Baden-Wurttemberg, Germany)</i> 11(30) e2400700–None. DOI:<a href=\"https://doi.org/10.1002/advs.202400700\">10.1002/advs.202400700</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38845188/\">https://pubmed.ncbi.nlm.nih.gov/38845188</a></p></li><li><p>Maizel, AS, &amp; Bookstein, JJ (1986). Streptokinase, urokinase, and tissue plasminogen activator: pharmacokinetics, relative advantages, and methods for maximizing rates and consistency of lysis. <i>Cardiovascular and interventional radiology</i> 9(5-6) 236–244. DOI:<a href=\"https://doi.org/10.1007/BF02577952\">10.1007/BF02577952</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3100038/\">https://pubmed.ncbi.nlm.nih.gov/3100038</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AD04;
